XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Employee Benefits and Share-Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract] |
Employee Benefits and Share-Based Compensation | Employee Benefits and Share-Based Compensation Share-Based Compensation Expense The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023:
| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  |  |  |
| (In thousands)
Cost of product and service revenues | $ | 1,555 |  |  | $ | 2,008 |  |  |  |  |
Research and development | 1,075 |  |  | 1,606 |  |  |  |  |
Selling, general, and administrative | 6,011 |  |  | 10,428 |  |  |  |  |
Total share-based compensation expense | $ | 8,641 |  |  | $ | 14,042 |  |  |  |  |
During the three months ended March 31, 2024 and 2023, the Company capitalized approximately $0.7 million and $1.1 million, respectively, of non-cash share-based compensation expense to internal-use and external-use software development costs related to internal labor. The Company did not capitalize any material non-cash share-based compensation expense to inventory during the three months ended March 31, 2024 and 2023. Employee Stock Purchase Plan (“ESPP”) The following assumptions were used to value shares under the ESPP for the three months ended March 31, 2024 and 2023:
| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  |  |  |
Expected life, years | 0.5 - 2.0 |  | 0.5 - 2.0 |  |  |  |
Expected volatility, % | 33.7% - 57.0% |  | 31.7% - 63.9% |  |  |  |
Risk-free interest rate, % | 1.5% - 5.5% |  | 0.1% - 5.1% |  |  |  |
Dividend yield, % | — | % |  | — | % |  |  |  |
For the three months ended March 31, 2024 and 2023, employees purchased approximately 334,000 and 209,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $24.06 and $46.96, respectively. As of March 31, 2024, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $1.5 million and is expected to be recognized over a weighted-average period of 1.6 years. Stock Options The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the three months ended March 31, 2023. There were no stock options granted during the three months ended March 31, 2024.
|  | Three Months Ended March 31, |  |
|  |  | 2023 |  |  |  |
Expected life, years |  |  | 3.2 |  |  |  |
Expected volatility, % |  |  | 44.8 | % |  |  |  |
Risk-free interest rate, % |  |  | 3.7 | % |  |  |  |
Estimated forfeiture rate, % |  |  | 10.0 | % |  |  |  |
Dividend yield, % |  |  | — | % |  |  |  |
The following table summarizes the stock option activity under the 2009 Plan during the three months ended March 31, 2024:
| Number of Shares |  | Weighted-Average Exercise Price |  | Weighted-Average Remaining Years |  | Aggregate Intrinsic Value
| (In thousands, except per share data)
Outstanding at December 31, 2023 | 2,023 |  |  | $ | 67.68 |  |  | 4.6 |  | $ | 1,013 |
Granted | — |  |  | — |  |  |  |  |
Exercised | — |  |  | — |  |  |  |  |
Expired | (117) |  |  | 73.88 |  |  |  |  |
Forfeited | (17) |  |  | 62.81 |  |  |  |  |
Outstanding at March 31, 2024 | 1,889 |  |  | $ | 67.35 |  |  | 4.4 |  | $ | 88 |
Exercisable at March 31, 2024 | 1,766 |  |  | $ | 66.74 |  |  | 4.4 |  | $ | 88 |
Vested and expected to vest at March 31, 2024 and thereafter | 1,882 |  |  | $ | 67.30 |  |  | 4.4 |  | $ | 88 |
As of March 31, 2024, total unrecognized compensation cost related to unvested stock options was $1.8 million, which is expected to be recognized over a weighted-average vesting period of 0.5 years. Restricted Stock Units (“RSUs”) The following table summarizes the RSU activity under the 2009 Plan during the three months ended March 31, 2024:
| Number of Shares |  | Weighted-Average Grant Date Fair Value |  | Weighted-Average Remaining Years |  | Aggregate Intrinsic Value
| (In thousands, except per share data)
Outstanding at December 31, 2023 | 1,078 |  |  | $ | 84.66 |  |  | 1.5 |  | $ | 40,551 |
Granted (Awarded) | 178 |  |  | 27.37 |  |  |  |  |
Vested (Released) | (73) |  |  | 94.23 |  |  |  |  |
Forfeited | (56) |  |  | 82.70 |  |  |  |  |
Outstanding and unvested at March 31, 2024 | 1,127 |  |  | $ | 75.08 |  |  | 1.5 |  | $ | 32,952 |
As of March 31, 2024, total unrecognized compensation cost related to RSUs was $52.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.0 years. Restricted Stock Awards (“RSAs”) The following table summarizes the RSA activity under the 2009 Plan during the three months ended March 31, 2024:
| Number of Shares |  | Weighted-Average Grant Date Fair Value
| (In thousands, except per share data)
Outstanding at December 31, 2023 | 24 |  |  | $ | 70.96 |
Granted (Awarded) | 3 |  |  | 32.45 |
Vested (Released) | (3) |  |  | 72.02 |
Outstanding and unvested at March 31, 2024 | 24 |  |  | $ | 66.81 |
As of March 31, 2024, total unrecognized compensation cost related to RSAs was $0.2 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.1 years. Performance-Based Stock Unit Awards (“PSUs”) The following table summarizes the PSU activity under the 2009 Plan during the three months ended March 31, 2024:
| Number of Shares |  | Weighted-Average Grant Date Fair Value
| (In thousands, except per share data)
Outstanding at December 31, 2023 | 75 |  |  | $ | 127.14 |
Granted | 177 |  |  | 28.67 |
Vested | — |  |  | — |
Forfeited | (65) |  |  | 122.29 |
Outstanding and unvested at March 31, 2024 | 187 |  |  | $ | 35.79 |
As of March 31, 2024, total unrecognized compensation cost related to PSUs was approximately $6.8 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.0 years. Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of March 31, 2024:
| Number of Shares
| (In thousands)
Stock options outstanding | 1,889 |
Non-vested restricted stock awards | 1,338 |
Shares authorized for future issuance | 2,354 |
ESPP shares available for future issuance | 2,916 |
Total shares reserved for future issuance | 8,497 |
Stock Repurchase Programs On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). During the first quarter of 2022, the 2014 Repurchase Program was completed, and as of March 31, 2024, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million. The timing, price, and volume of repurchases are to be based on market conditions, relevant securities laws, and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions, or pursuant to a Rule 10b-18 plan, subject to the terms and conditions of the Second A&R Credit Agreement, as amended. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time. During the three months ended March 31, 2024 and 2023, the Company did not repurchase any of its outstanding common stock under the 2016 Repurchase Program.

X
- Definition The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//710/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//712/tableOfContent Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//715/tableOfContent Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_CompensationAndEmployeeBenefitPlansTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration